-
1Academic Journal
المؤلفون: D. V. Nevzorova, A. V. Sidorov, A. I. Ustinova, A. V. Morev, E. L. Krakauer, G. R. Abuzarova, S. R. Connor, M. Chwistek, T. A. Kunyaeva, S. Michaelson, Д. В. Невзорова, А. В. Сидоров, А. И. Устинова, А. В. Морев, Э. Л. Кракауэр, Г. Р. Абузарова, С. Р. Коннор, М. Чвистек, Т. А. Куняева, С. Майкалсон
المصدر: PULMONOLOGIYA; Том 31, № 1 (2021); 109-115 ; Пульмонология; Том 31, № 1 (2021); 109-115 ; 2541-9617 ; 0869-0189
مصطلحات موضوعية: кислородотерапия, refractory dyspnea, palliative care, opioid analgesics, oxygen therapy, рефрактерная одышка, паллиативная медицинская помощь, опиоидные анальгетики
وصف الملف: application/pdf
Relation: https://journal.pulmonology.ru/pulm/article/view/2273/1823; Российское респираторное общество. Диагностика и лечение идиопатического легочного фиброза: Федеральные клинические рекомендации. М.; 2016. Доступно на: https://spulmo.ru/download/IPFrec.pdf; Lederer D.J., Martinez F.J. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 2018; 378 (19): 1811-1823. DOI:10.1056/nejmra1705751.; Raghu G., Chen S.Y., Yeh W.S. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-2011. Lancet Respir. Med. 2014; 2 (7): 566-572. DOI:10.1016/s2213-2600(14)70101-8.; Strongman H., Kausar I., Maher T.M. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv. Ther. 2018; 35 (5): 724-736. DOI:10.1007/s12325-018-0693-1.; Richeldi L., Rubin A.S., Avdeev S. et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med. 2015; 13: 237. DOI:10.1186/s12916-015-0495-0.; Tang Y.W., Johnson J.E., Browning P.J. et al. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Microbiol. 2003; 41 (6): 2633-2640. DOI:10.1128/jcm.41.6.2633-2640.2003.; Manika K., Alexiou-Daniel S., Papakosta D. et al. A. Epstein-Barr virus DNA in bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc. Diffuse Lung Dis. 2007; 24 (2): 134-140.; Kelly B.G., Lok S.S., Hasleton P.S. et al. A rearranged form of Epstein-Barr virus DNA is associated with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2002; 166 (4): 510-513. DOI:10.1164/rccm.2103058.; Kropski J.A., Lawson W.E., Blackwell T.S. Right place, right time: the evolving role of herpesvirus infection as a “second hit” in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012; 302 (5): L441-444. DOI:10.1152/ajplung.00335.2011.; Bjoraker J.A., Ryu J.H., Edwin M.K. et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157 (1): 199-203. DOI:10.1164/ajrccm.157.1.9704130.; Ley B., Ryerson C.J., Vittinghoff E. et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156 (10): 684-691. DOI:10.7326/0003-4819-156-10-201205150-00004.; Homma S., Bando M., Azuma A. et al. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir. Investig. 2018; 56 (4): 268-291. DOI:10.1016/j.resinv.2018.03.003.; Martinez F.J., Safrin S., Weycker D. et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann. Intern. Med. 2005; 142 (12, Pt 1): 963-967. DOI:10.7326/0003-4819-142-12_part_1-200506210-00005.; King T.E. Jr, Albera C., Bradford W.Z. et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am. J. Respir. Crit. Care Med. 2014; 189 (7): 825-831. DOI:10.1164/rccm.201311-1951OC.; Rozenberg D., Sitzer N., Porter S. et al. Idiopathic pulmonary fibrosis: A review of disease, pharmacological, and nonpharmacological strategies with a focus on symptoms, function, and health-related quality of life. J. Pain. Symptom. Manage. 2020; 59 (6): 1362-1378. DOI:10.1016/j.jpainsym-man.2019.12.364.; Webb M., Moody L.E., Mason L.A. Dyspnoea assessment and management in hospice patients with pulmonary disorders. Am. J. Hosp. Palliat. Care. 2000; 17 (4): 259-264. DOI:10.1177/104990910001700412.; Ripamonti C. Management of dyspnea in advanced cancer patients. Support. Cancer Care. 1999; 7: 233-243. DOI:10.1007/s005200050255.; Allen S., Raut S., Woollard J., Vassallo M. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliative Med. 2005; 19 (2): 128-130. DOI:10.1191/0269216305pm998oa.; Lanken P.N., Terry P.B., DeLisser H.M. et al. An official American Thoracic Society clinical policy statement: Palliative care for patients with respiratory diseases and critical illnesses. Am. J. Respir. Crit. Care Med. 2008; 177 (8): 912-927. DOI:10.1164/rccm.200605-587ST.; Muers M.F. Opioids for dyspnoea. Thorax. 2002; 57 (11): 922-923. DOI:10.1136/thorax.57.11.922.; Twycross R., Wilcock A., eds. Introducing Palliative Care. 5th Edn. Palliativedrugs.com Ltd; 2016.; Jennings A.L., Davies A.N., Higgins J.P.T. et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002; 57 (11): 939-944. DOI:10.1136/thorax.57.11.939.; SIGN. Management of chronic pain (SIGN 136). Edinburgh: SIGN; 2013. Available at: http://www.sign.ac.uk [Accessed: December, 2013].; Trivedi M., Shaikh S., Gwinnut C. Pharmacology of Opioids. Update in Anaesthesia. Originally published in Anaesthesia Tutorial of the Week; 2007: 118-124. Available at: http://e-safe-anaesthesia.org/e_library/03/Opioid_pharmacology_Update_2008.pdf; Parshall M.B., Schwartzstein R.M., Adams L. et al. An official American Thoracic Society statement: Update on the mechanisms, assessment, and management of dyspnea. Am. J. Respir. Crit. Care Med. 2012; 185 (4): 435-452. DOI:10.1164/rccm.201111-2042ST.; Mahler D.A., Selecky P.A., Harrod C.G. et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest. 2010; 137 (3): 674-691. DOI:10.1378/chest.09-1543.; Boscarino J.A., Rukstalis M., Hoffman S.N. et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction. 2010; 105 (10): 1776-1782. DOI:10.1111/j.1360-0443.2010.03052.x.; Arthur J., Edwards T., Reddy S. et al. Outcomes of a specialized interdisciplinary approach for patients with cancer with aberrant opioid-related behavior. Oncologist. 2018; 23 (2): 263-270. DOI:10.1634/theoncologist.2017-0248.; https://journal.pulmonology.ru/pulm/article/view/2273